Forma Therapeutics Holdings logo
Forma Therapeutics Holdings FMTX

Quarterly report 2022-Q2
added 12-23-2023

report update icon

Forma Therapeutics Holdings Balance Sheet 2011-2026 | FMTX

Annual Balance Sheet Forma Therapeutics Holdings

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-44.7 M - - -83.4 M - - - - - - -

Long Term Debt

27.6 M - - - - - - - - - -

Long Term Debt Current

5.12 M - - - - - - - - - -

Total Non Current Liabilities

- 1.03 M 2.62 M 11.9 M - - - - - - -

Total Current Liabilities

35.1 M 31.7 M 24.9 M - - - - - - - -

Total Liabilities

62.7 M 32.7 M 26.7 M 246 M - - - - - - -

Deferred Revenue

- 1.24 M 1.24 M 203 M - - - - - - -

Retained Earnings

-230 M -57.4 M 16.7 M -54.6 M - - - - - - -

Total Assets

561 M 681 M 183 M 263 M - - - - - - -

Cash and Cash Equivalents

77.4 M 283 M 174 M - - - - - - - -

Book Value

498 M 648 M 156 M 17.6 M - - - - - - -

Total Shareholders Equity

498 M 648 M 18.2 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Forma Therapeutics Holdings

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - 27 M 27.6 M 26.8 M 2.87 M - - 5.21 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - 60.7 M 53.3 M 62.7 M 59.4 M 34 M - 32.7 M 32.7 M 29 M 32.7 M 26.7 M 26.7 M 26.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - 1.24 M - - 1.24 M 1.24 M 1.24 M 6.43 M - 94 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - -327 M -275 M -230 M -180 M -137 M - -57.4 M -57.4 M -1.21 M -57.4 M 16.7 M 16.7 M 16.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - 475 M 514 M 561 M 602 M 613 M - 681 M 681 M 468 M 681 M 183 M 183 M 183 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - 74.4 M 77.4 M 87.2 M 50.9 M 97.8 M 283 M 283 M 283 M 283 M 173 M 173 M 173 M - 84.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - 414 M 461 M 498 M 543 M 579 M - 648 M 648 M 438 M 648 M 156 M 156 M 156 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - 414 M 461 M 498 M 543 M 579 M 616 M 648 M 416 M 438 M 28.8 M 18.2 M 18.2 M 83.4 M 98.2 M -48.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Forma Therapeutics Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.57 -3.68 % $ 184 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 16.87 -2.49 % $ 789 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 7.47 -4.6 % $ 205 M israelIsrael
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 30.26 1.0 % $ 814 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Exelixis Exelixis
EXEL
$ 50.13 -1.9 % $ 13.6 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.41 4.78 % $ 67.2 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Forte Biosciences Forte Biosciences
FBRX
$ 23.11 -3.55 % $ 299 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 4.09 -7.05 % $ 1.22 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.63 2.52 % $ 434 M britainBritain
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioNTech SE BioNTech SE
BNTX
$ 89.55 -2.65 % $ 21.6 B germanyGermany
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 2.17 -7.66 % $ 139 M usaUSA
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Gilead Sciences Gilead Sciences
GILD
$ 129.58 -1.88 % $ 161 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 3.36 -3.72 % $ 5.53 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 0.72 -1.58 % $ 32.9 M israelIsrael
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.12 - $ 649 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Genmab A/S Genmab A/S
GMAB
$ 26.54 -1.34 % $ 1.72 B danmarkDanmark
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA